Eli Lilly acquires AtaiBeckley for $3.8B, signaling Big Pharma's major bet on psychedelic medicine

Eli Lilly has announced a significant acquisition of AtaiBeckley for up to $3.8 billion, marking the largest deal in the psychedelic medicine sector. This move, along with AbbVie's prior acquisition, signals a major shift as large pharmaceutical companies are now investing heavily in psychedelic therapies for mental health conditions. The acquisition is driven by promising scientific data and the potential for market success, bolstered by recent regulatory tailwinds and successful commercial precedents like Johnson & Johnson's Spravato. AI

RANK_REASON Major acquisition by a top-tier pharmaceutical company in a rapidly developing therapeutic area. [lever_c_demoted from significant: ic=1 ai=0.0]

Read on Forbes — Innovation →

• AbbVie
• AtaiBeckley
• BPL-003
• COMP360
• Compass Pathways
• Definium Therapeutics
• President Trump
• DT120
• Eli Lilly
• Gilgamesh Pharmaceuticals
• Johnson & Johnson
• Spravato
• FDA

• funding
• product
• policy

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →